Formulary
Human papillomavirus vaccine: Indications, Dosing, Side Effects and Interactions
For human papillomavirus vaccine Human papillomavirus vaccine is a non-live vaccine that contains adsorbed virus-like particles made from recombinant proteins.
MedNext Academy | 4 min read
Human papillomavirus vaccine: Indications, Dosing, Side Effects and Interactions
For human papillomavirus vaccine Human papillomavirus vaccine is a non-live vaccine that contains adsorbed virus-like particles made from recombinant proteins.
Drug action
For human papillomavirus vaccine Human papillomavirus vaccine is a non-live vaccine that contains adsorbed virus-like particles made from recombinant proteins.
Indications and dose
**Primary immunisation against HPV-related premalignant lesions and cancer (cervical, vulvar, vaginal, and anal) and genital warts [1-dose schedule]**
- **Child** (By Intramuscular Injection): 11-17 years 0.5 mL for 1 dose.
- **Adult** (By Intramuscular Injection): 18-24 years 0.5 mL for 1 dose.
**Immunisation against HPV-related premalignant lesions and cancer (cervical, vulvar, vaginal, and anal) and genital warts [2-dose schedule**
- **Adult** (By Intramuscular Injection): for gay, bisexual and other men who have sex with men, and other at risk individuals] 25-45 years 0.5 mL for 1 dose, followed by 0.5 mL for 1 dose, second dose to be given 6-24 months after the first dose, if the 2-dose schedule is interrupted, it should be resumed but not repeated, even if more than 24 months have elapsed since the first dose.
**Immunisation against HPV-related premalignant lesions and cancer (cervical, vulvar, vaginal, and anal) and genital warts [3-dose schedule**
- **Child** (By Intramuscular Injection): for immunocompromised or HIV-positive patients] 11-17 years 0.5 mL for 1 dose, followed by 0.5 mL for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL for 1 dose, third dose to be given at least 3 months after the second dose, the 3-dose schedule should be completed within 12 months of the first dose, if the schedule is interrupted, it should be resumed but not repeated, allowing the appropriate interval between the remaining doses.
- **Adult** (By Intramuscular Injection): 0.5 mL for 1 dose, followed by 0.5 mL for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL for 1 dose, third dose to be given at least 3 months after the second dose, the 3-dose schedule should be completed within 12 months of the first dose, if the schedule is interrupted, it should be resumed but not repeated, allowing the appropriate interval between the remaining doses.
**Primary immunisation against HPV-related premalignant lesions and cancer (cervical, vulvar, vaginal, and anal) and genital warts [1-dose schedule] for human papillomavirus vaccine**
- **Child 11-17 years** (By intramuscular injection): 0.5 mL for 1 dose.
**Immunisation against HPV-related premalignant lesions and cancer (cervical, vulvar, vaginal, and anal) and genital warts [3-dose schedule for immunocompromised or HIV-positive patients] for human papillomavirus vaccine**
- **Child 11-17 years** (By intramuscular injection): 0.5 mL for 1 dose, followed by 0.5 mL for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL for 1 dose, third dose to be given at least 3 months after the second dose, the 3-dose schedule should be completed within 12 months of the first dose, if the schedule is interrupted, it should be resumed but not repeated, allowing the appropriate interval between the remaining doses.
Cautions
For all vaccines, general Acute illness; minor illnesses Cautions, further information Illness UKHSA advises vaccination may be postponed if the individual is suffering from an acute illness; however, it is not necessary to postpone immunisation in patients with minor illnesses without fever or systemic upset. Predisposition to neurological problems UKHSA advises: when there is a personal or family history of febrile convulsions, there is an increased risk of these occurring during fever from any cause including immunisation, but this is not a contra-indication to immunisation. In children who have had a seizure associated with fever without neurological deterioration, immunisation is recommended ; advice on the management of fever should be given before immunisation. When a child has had a convulsion not associated with fever, and the neurological condition is not deteriorating, immunisation is recommended ; children with stable neurological disorders (e.g. spina bifida, congenital brain abnormality, and peri-natal hypoxic-ischaemic encephalopathy) should be immunised according to the recommended schedule; when there is a still evolving neurological problem , including poorly controlled epilepsy, immunisation should be deferred and the child referred to a specialist. Immunisation is recommended if a cause for the neurological disorder is identified. If a cause is not identified, immunisation should be deferred until the condition is stable. Impaired immune response and drugs affecting immune response Immune response to vaccines may be reduced in immunosuppressed patients, UKHSA advises consider seeking specialist advice.
Side effects
For all vaccines, general Common or very common Abdominal pain; appetite decreased; arthralgia; diarrhoea; dizziness; fatigue; fever; headache; lymphadenopathy; malaise; myalgia; nausea; skin reactions; vomiting Uncommon Hypersensitivity Side-effects For human papillomavirus vaccine Uncommon Asthenia; chills; syncope Frequency not known Acute disseminated encephalomyelitis; bronchospasm; Guillain-Barre syndrome; immune thrombocytopenic purpura
Pregnancy
For human papillomavirus vaccine Not known to be harmful, but vaccination should be postponed until completion of pregnancy.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Human papillomavirus vaccine in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary